Ocera Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of clinical candidates for the treatment of gastrointestinal and liver diseases announced today that it has raised a $12 million Series B financing. The financing
will be used to continue clinical development of the company's first product,
AST-120. A pivotal Phase III clinical trial for AST-120 was initiated in the first
quarter of 2006 for the treatment of fistulizing Crohn's disease. The Series B
round was led by new investor, Sofinnova Ventures. Previous investors, Domain
Associates, LLC and Thomas, McNerney & Partners, LLC also participated in
this financing.
BioSpace
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Stakeholders Urge Congress to Update Clinical Laboratory Diagnostics Legislation
The letter to lawmakers cites an urgent need to reform regulations covering laboratory developed tests and in vitro diagnostics.
Seniors Paying More for Generics Through Medicare Part D, Study Finds
The higher cost sharing did not correspond with an increase in the underlying price of generic drugs, Avalere said.
FDAnews Drug Daily Bulletin
OCERA THERAPEUTICS, INC. RAISES $12 MILLION SERIES B FINANCING
July 11, 2006